Content provided in partnership with
Technology Industry
Industry: Email Alert RSS FeedIncara Pharmaceuticals Corp
BT Catalyst, Dec, 2000
Incara Pharmaceuticals Corp. (Nasdaq: INCR) of Reseach Triangle Park reported recently that its catalytic antioxidant molecule, AEOL 10113, significantly reduced specific markers of oxygen-radical damage to the brain when administered after the obstruction of blood flow in a well-recognized model of stroke in rats.
- Most Popular Articles in Technology
- An overview of continuous data protection
- Why all those current ratings?
- Many countries now have a mobile penetration rate above 100%, report says
- The Tata Group's big telecom gamble: VSNL's recent acquisition of Tyco ...
- MEASURING BANK BRANCH EFFICIENCY USING DATA ENVELOPMENT ANALYSIS: MANAGERIAL ...
- More »
In a separate experiment, this compound when administered intravenously reduced cortical and sub-cortical infarct volume, and improved neurological recovery in a mouse model of stroke. Assuming satisfactory completion of preclinical studies, Incara intends to initiate clinical trials with one of its catalytic antioxidants for treatment of stroke in 2001.
COPYRIGHT 2000 North Carolina Biotechnology Center
COPYRIGHT 2008 Gale, Cengage Learning
Find Research Guides for:
Find Featured Titles for: Home & Garden
Most Popular Articles in Technology
- An overview of continuous data protection
- Why all those current ratings?
- Many countries now have a mobile penetration rate above 100%, report says
- The Tata Group's big telecom gamble: VSNL's recent acquisition of Tyco ...
- MEASURING BANK BRANCH EFFICIENCY USING DATA ENVELOPMENT ANALYSIS: MANAGERIAL ...
- More »